Learning and validating clinically meaningful phenotypes from electronic health data

The ever-growing adoption of electronic health records (EHR) to record patients' health journeys has resulted in vast amounts of heterogeneous, complex, and unwieldy information [Hripcsak and Albers, 2013]. Distilling this raw data into clinical insights presents great opportunities and challenges for the research and medical communities. One approach to this distillation is called computational phenotyping. Computational phenotyping is the process of extracting clinically relevant and interesting characteristics from a set of clinical documentation, such as that which is recorded in electronic health records (EHRs). Clinicians can use computational phenotyping, which can be viewed as a form of dimensionality reduction where a set of phenotypes form a latent space, to reason about populations, identify patients for randomized case-control studies, and extrapolate patient disease trajectories. In recent years, high-throughput computational approaches have made strides in extracting potentially clinically interesting phenotypes from data contained in EHR systems. Tensor factorization methods have shown particular promise in deriving phenotypes. However, phenotyping methods via tensor factorization have the following weaknesses: 1) the extracted phenotypes can lack diversity, which makes them more difficult for clinicians to reason about and utilize in practice, 2) many of the tensor factorization methods are unsupervised and do not utilize side information that may be available about the population or about the relationships between the clinical characteristics in the data (e.g., diagnoses and medications), and 3) validating the clinical relevance of the extracted phenotypes requires domain training and expertise. This dissertation addresses all three of these limitations. First, we present tensor factorization methods that discover sparse and concise phenotypes in unsupervised, supervised, and semi-supervised settings. Second, via two tools we built, we show how to leverage domain expertise in the form of publicly available medical articles to evaluate the clinical validity of the discovered phenotypes. Third, we combine tensor factorization and the phenotype validation tools to guide the discovery process to more clinically relevant phenotypes.Computational Science, Engineering, and Mathematic

Pacific Symposium on Biocomputing 2023

The Pacific Symposium on Biocomputing (PSB) 2023 is an international, multidisciplinary conference for the presentation and discussion of current research in the theory and application of computational methods in problems of biological significance. Presentations are rigorously peer reviewed and are published in an archival proceedings volume. PSB 2023 will be held on January 3-7, 2023 in Kohala Coast, Hawaii. Tutorials and workshops will be offered prior to the start of the conference.PSB 2023 will bring together top researchers from the US, the Asian Pacific nations, and around the world to exchange research results and address open issues in all aspects of computational biology. It is a forum for the presentation of work in databases, algorithms, interfaces, visualization, modeling, and other computational methods, as applied to biological problems, with emphasis on applications in data-rich areas of molecular biology.The PSB has been designed to be responsive to the need for critical mass in sub-disciplines within biocomputing. For that reason, it is the only meeting whose sessions are defined dynamically each year in response to specific proposals. PSB sessions are organized by leaders of research in biocomputing's 'hot topics.' In this way, the meeting provides an early forum for serious examination of emerging methods and approaches in this rapidly changing field

Artificial Intelligence in Oncology Drug Discovery and Development

There exists a profound conflict at the heart of oncology drug development. The efficiency of the drug development process is falling, leading to higher costs per approved drug, at the same time personalised medicine is limiting the target market of each new medicine. Even as the global economic burden of cancer increases, the current paradigm in drug development is unsustainable. In this book, we discuss the development of techniques in machine learning for improving the efficiency of oncology drug development and delivering cost-effective precision treatment. We consider how to structure data for drug repurposing and target identification, how to improve clinical trials and how patients may view artificial intelligence